Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
AVIR

AVIR - Atea Pharmaceuticals Inc Stock Price, Fair Value and News

4.24USD-0.09 (-2.08%)Delayed as of 21 Feb 2024, 02:03 pm ET
Watchlist

Market Summary

USD4.24-0.09
Delayedas of 21 Feb 2024, 02:03 pm
-2.08%

AVIR Alerts

  • 1 major insider sales recently.

AVIR Stock Price

View Fullscreen

AVIR RSI Chart

AVIR Valuation

Market Cap

361.3M

Price/Earnings (Trailing)

-2.75

Price/Sales (Trailing)

0.92

EV/EBITDA

-1.72

Price/Free Cashflow

-4.25

AVIR Price/Sales (Trailing)

AVIR Profitability

EBT Margin

-37.12%

Return on Equity

-22.56%

Return on Assets

-21.58%

Free Cashflow Yield

-23.56%

AVIR Fundamentals

AVIR Revenue

Revenue (TTM)

351.4M

Rev. Growth (Yr)

576.2%

Rev. Growth (Qtr)

15.94%

AVIR Earnings

Earnings (TTM)

-131.2M

Earnings Growth (Yr)

-310.89%

Earnings Growth (Qtr)

-17.6%

Breaking Down AVIR Revenue

52 Week Range

2.885.19
(Low)(High)

Last 7 days

-3.3%

Last 30 days

15.7%

Last 90 days

36.0%

Trailing 12 Months

-2.1%

How does AVIR drawdown profile look like?

AVIR Financial Health

Current Ratio

31.93

AVIR Investor Care

Shares Dilution (1Y)

0.18%

Diluted EPS (TTM)

-1.58

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20230000
20220000
2021124.3M200.0M275.7M351.4M
202000048.6M

Tracking the Latest Insider Buys and Sells of Atea Pharmaceuticals Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 01, 2024
hammond janet mj
sold
-53,913
3.843
-14,029
chief development officer
Feb 01, 2024
vavricka john
sold
-45,420
3.843
-11,819
chief commercial officer
Feb 01, 2024
horga maria arantxa
sold
-60,963
3.8414
-15,870
chief medical officer
Feb 01, 2024
foster wayne
sold
-47,904
3.8394
-12,477
evp, chief accounting officer
Feb 01, 2024
corcoran andrea
sold
-60,914
3.8449
-15,843
see remarks
Feb 01, 2024
sommadossi jean-pierre
sold
-218,819
3.845
-56,910
president, ceo, and chairman
Jan 31, 2024
hammond janet mj
acquired
-
-
46,800
chief development officer
Jan 31, 2024
vavricka john
acquired
-
-
33,334
chief commercial officer
Jan 31, 2024
horga maria arantxa
acquired
-
-
41,534
chief medical officer
Jan 31, 2024
foster wayne
acquired
-
-
33,334
evp, chief accounting officer

1–10 of 27

Which funds bought or sold AVIR recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
reduced
-46.14
-378,000
457,000
0.04%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
added
30.6
42,000
169,000
-%
Feb 16, 2024
PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO
unchanged
-
937
54,937
-%
Feb 16, 2024
O'Dell Group, LLC
new
-
610
610
-%
Feb 15, 2024
BARCLAYS PLC
added
669
524,000
601,000
-%
Feb 15, 2024
Legal & General Group Plc
unchanged
-
302
18,434
-%
Feb 15, 2024
JANE STREET GROUP, LLC
added
431
195,742
240,166
-%
Feb 15, 2024
Virtus ETF Advisers LLC
sold off
-100
-72,549
-
-%
Feb 15, 2024
Farther Finance Advisors, LLC
added
56.52
245
659
-%
Feb 14, 2024
AQR CAPITAL MANAGEMENT LLC
sold off
-100
-91,059
-
-%

1–10 of 45

Are Funds Buying or Selling AVIR?

Are funds buying AVIR calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AVIR
No. of Funds

Unveiling Atea Pharmaceuticals Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
ecor1 capital, llc
8.4%
6,995,861
SC 13G/A
Feb 14, 2024
ecor1 capital, llc
8.4%
6,995,861
SC 13G/A
Feb 14, 2024
ecor1 capital, llc
8.4%
6,995,861
SC 13G/A
Feb 13, 2024
sommadossi jean-pierre
7.1%
5,925,000
SC 13G/A
Feb 13, 2024
vanguard group inc
5.51%
4,599,710
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Feb 07, 2024
bml investment partners, l.p.
6.7%
5,462,079
SC 13G
Feb 07, 2024
bml investment partners, l.p.
6.7%
5,462,079
SC 13G/A
Jan 24, 2024
blackrock inc.
11.3%
9,443,887
SC 13G/A
Nov 28, 2023
tang capital partners lp
4.8%
4,033,463
SC 13D/A

Recent SEC filings of Atea Pharmaceuticals Inc

View All Filings
Date Filed Form Type Document
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 09, 2024
SC 13G/A
Major Ownership Report
Feb 07, 2024
SC 13G
Major Ownership Report
Feb 07, 2024
SC 13G/A
Major Ownership Report
Feb 02, 2024
4
Insider Trading
Feb 02, 2024
4
Insider Trading

Peers (Alternatives to Atea Pharmaceuticals Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
33.2B
9.1B
-16.59% -47.80%
-9.57
3.64
-57.36% -129.46%
32.0B
-
-0.77% 465779.94%
-3.7K
218.4K
- -102.45%
18.9B
1.8B
-23.99% -31.71%
-42.82
10.31
76.23% 61.08%
16.7B
2.3B
-4.89% -18.90%
113.61
7.23
15.05% 75.21%
13.2B
3.7B
-7.62% -26.87%
22.1
3.57
8.87% 75.42%
MID-CAP
8.0B
272.9M
-2.06% 34.31%
-13.27
29.46
141.38% 4.43%
6.3B
107.9M
-3.85% 226.12%
-10.03
54.1
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.42
6.46
23.54% 31.53%
3.8B
223.4M
8.92% 47.81%
-19.02
17.18
-35.86% -26.24%
3.6B
240.7M
-19.08% -10.99%
-12.2
15.04
-1.03% -92.09%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
23.7
4.22
81.69% -7.29%
490.6M
1.0B
-9.17% -57.89%
-0.89
0.47
-43.15% 58.48%
185.9M
4.9M
-14.18% -58.18%
-1.13
38.02
-57.57% 50.48%
103.1M
881.7K
289.54% 381.25%
-2.17
112.79
-77.61% -13.74%
4.4M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Atea Pharmaceuticals Inc News

Latest updates
InvestorsObserver15 Feb 202408:38 pm
Yahoo Finance10 Jan 202408:00 am
Seeking Alpha09 Jan 202408:00 am

Atea Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In null)
Income Statement (Quarterly)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q4
Revenue15.9%7.006.005.003.001.0097.0019233.0060.0066.00-
Operating Expenses-15.2%35.0042.0040.0016.0032.0042.0071.0055.0052.0035.0028.00
  S&GA Expenses4.4%13.0013.0012.0011.0012.0013.0013.0012.0012.009.0014.00
  R&D Expenses-23.8%22.0029.0028.005.0020.0030.0058.0043.0040.0027.0014.00
EBITDA Margin3.0%-0.31*-0.32*-0.34*0.10*0.07*0.19*0.39*0.14*0.21*0.19*-0.22*
Income Taxes27.4%0.000.000.00-3.830.00--6.007.00--
Earnings Before Taxes20.8%-27.93-35.27-34.31-11.90-31.21-42.08121-22.099.0031.0021.00
EBT Margin2.9%-0.31*-0.32*-0.34*0.10*0.07*0.19*0.39*0.14*0.21*0.19*-0.23*
Net Income20.5%-28.18-35.47-34.43-8.07-31.33-42.08117-28.192.0031.0021.00
Net Income Margin2.9%-0.30*-0.31*-0.33*0.10*0.04*0.14*0.34*0.09*0.18*0.19*-0.23*
Free Cashflow46.0%-16.12-29.85-21.54-21.26-21.06-59.05-75.4323.00-17.35-16.84319
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q4
Assets-2.9%608626638667687694717773844872841864110---
  Current Assets-2.8%603621632661682689713772843871840863108--22.00
    Cash Equivalents-35.5%13821418318817668470676584081683485010511617.0022.00
  Net PPE-6.9%1.001.002.002.002.002.001.000.000.000.000.000.000.00--0.00
Liabilities11.3%26.0024.0020.0026.0023.0034.0037.0063.00262274254316----
  Current Liabilities16.9%19.0016.0012.0018.0016.0025.0029.0057.0026227425431611.00--2.00
Shareholder's Equity-3.4%5826026186416636606807105815985865489.005.005.005.00
  Retained Earnings-26.8%-156-123-95.35-59.88-25.45-17.3814.0056.00-61.10-32.91-34.45-65.16-85.82---54.21
  Additional Paid-In Capital1.7%7397267147016896786666546426316216139.00--5.00
Shares Outstanding0.0%83.0083.0083.0083.0083.0083.0083.0083.0083.0083.0083.0022.00----
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations-9.1%-17,591-16,120-29,850-21,545-21,242-19,186-59,009-75,42322,603-17,348-16,837318,521-9,481-7,798-4,508-3,943----
  Share Based Compensation0.2%12,38312,35312,53511,64511,50411,90811,66111,35110,99010,0077,2732,8214,238209189174----
Cashflow From Investing-225.7%-58,51346,56524,48033,488-486,975-1,879-44.00-----5.00-15.00-------
Cashflow From Financing-92.00-165-147-22314279557.00471426,218-913106,449-6.00-----

AVIR Income Statement

2023-09-30
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Operating expenses:    
Research and development$ 28,181$ 4,905$ 79,198$ 54,396
General and administrative12,60411,37638,39136,355
Total operating expenses40,78516,281117,58990,751
Loss from operations(40,785)(16,281)(117,589)(90,751)
Interest income and other, net7,8644,38221,4665,560
Loss before income taxes(32,921)(11,899)(96,123)(85,191)
Income tax benefit (expense)(221)3,833(669)3,713
Net loss(33,142)(8,066)(96,792)(81,478)
Other comprehensive income (loss):    
Unrealized gain (loss) on available-for-sale investments48(855)422(855)
Comprehensive loss$ (33,094)$ (8,921)$ (96,370)$ (82,333)
Net loss per share - basic and diluted    
Basic$ (0.40)$ (0.10)$ (1.16)$ (0.98)
Diluted$ (0.40)$ (0.10)$ (1.16)$ (0.98)
Weighted-average number of common shares used in computing net loss per share - basic and diluted    
Basic83,399,76983,258,53783,374,32883,231,146
Diluted83,399,76983,258,53783,374,32883,231,146

AVIR Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets  
Cash and cash equivalents$ 137,886$ 188,460
Marketable securities457,240458,249
Prepaid expenses and other current assets8,19014,213
Total current assets603,316660,922
Property and equipment, net1,3931,705
Restricted cash 198
Other assets1,3961,494
Operating lease right-of-use assets, net1,9702,389
Total assets608,075666,708
Current liabilities  
Accounts payable3952,551
Accrued expenses and other current liabilities17,74815,206
Current portion of operating lease liabilities750721
Total current liabilities18,89318,478
Operating lease liabilities1,8352,403
Income taxes payable5,6175,255
Total liabilities26,34526,136
Commitments and contingencies (see Note 12)
Stockholders’ equity:  
Preferred stock, $0.001 par value per share; 10,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.001 par value; 300,000,000 shares authorized; 83,435,513 and 83,287,639 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively8383
Additional paid-in capital738,580701,052
Accumulated other comprehensive loss(262)(684)
Accumulated deficit(156,671)(59,879)
Total stockholders’ equity581,730640,572
Total liabilities and stockholders’ equity$ 608,075$ 666,708
AVIR
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase III SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, a drug that is in Phase II clinical trial for the treatment and prophylaxis of dengue; and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, and Zika virus, as well as Ruzasvir, an investigational NS5A inhibitor for the treatment of chronic HCV infection. It also develops a co-formulated, oral, pan-genotypic fixed dose combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virous (HCV); It has a license agreement with Merck & Co, Inc. development, manufacture, and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
 CEO
 WEBSITEateapharma.com
 EMPLOYEES72

Atea Pharmaceuticals Inc Frequently Asked Questions


What is the ticker symbol for Atea Pharmaceuticals Inc? What does AVIR stand for in stocks?

AVIR is the stock ticker symbol of Atea Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Atea Pharmaceuticals Inc (AVIR)?

As of Tue Feb 20 2024, market cap of Atea Pharmaceuticals Inc is 361.28 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AVIR stock?

You can check AVIR's fair value in chart for subscribers.

What is the fair value of AVIR stock?

You can check AVIR's fair value in chart for subscribers. The fair value of Atea Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Atea Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AVIR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Atea Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether AVIR is over valued or under valued. Whether Atea Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Atea Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AVIR.

What is Atea Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Feb 20 2024, AVIR's PE ratio (Price to Earnings) is -2.75 and Price to Sales (PS) ratio is 0.92. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AVIR PE ratio will change depending on the future growth rate expectations of investors.